Monday, June 15, 2020

Nirapamib Plus Bevacizumab: a Winning Combo

Recent findings presented at the 2020 ASCO Virtual Scientific Program confirmed that combination nirapamib (Zejula) plus bevacizumab (Avastin) showed a 66% reduction in the risk of disease progression or death.

The results from this phase II study confirms earlier findings that showed improved clinical outcomes in the AVANOVA trial that were clinically significant.

Patients with recurrent platinum-sensitive epithelial, fallopian tube or peritoneal cancer and high-grade serous or endometrioid histology participated in the study. Additionally, patients with any number of prior therapies were allowed to participate.

The results of the study led by a group from Denmark is now set to move into phase III. If this continues to be successful, it will likely change treatment protocols for recurrent OC.

To read more about the study, follow this link.

No comments:

Post a Comment